Anti-Viral Compounds

The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 1. (S)-isopropyl 2-(((S)-(((2R ,3R ,4S ,5R)-4-bromo-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate , or a pharmaceutically acceptable salt thereof.2. Ethyl 2-(((((2R ,3R ,4R ,5R)-4-bromo-4-chloro-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.3. Ethyl 2-(((R)-(((2R ,3R ,4R ,5R)-4-bromo-4-chloro-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.4. Ethyl 2-(((S)-(((2R ,3R ,4R ,5R)-4-bromo-4-chloro-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1 (2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.5. Ethyl 2-(((S)-(((2R ,3R ,4S ,5R)-4-bromo-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.6. A method for treating HCV claim 1 , comprising administering a compound or salt of to an HCV patient.7. A method for treating HCV claim 2 , comprising administering a compound or salt of to an HCV patient.8. A method for treating HCV claim 3 , comprising administering a compound or salt of to an HCV patient.9. A method for treating HCV claim 4 , comprising administering a compound or salt of to an HCV patient.10. A method for treating HCV claim 5 , comprising administering a compound or salt of to an HCV patient.11. A pharmaceutical composition comprising a ...

Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV

Anti-viral compounds

The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

ANTIVIRAL COMPOUNDS AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 125-. (canceled)28. The compound or salt of claim 27 , wherein n is 1.29. The compound or salt of claim 27 , wherein n is 2.30. The compound or salt of claim 27 , wherein Ris amino.31. The compound or salt of claim 27 , wherein Ris tert-butoxycarbonylamino.33. The compound or salt of claim 32 , wherein m is 0.34. The compound or salt of claim 32 , wherein m is 2.35. The compound or salt of claim 32 , wherein Ris hydrogen.36. The compound or salt of claim 32 , wherein Ris phenyl.37. The compound or salt of claim 32 , wherein Ris C-C-alkyl.38. The compound or salt of claim 32 , wherein Ris C-C-alkyloxy-carbonyl.39. The compound or salt of claim 26 , wherein Ris benzoyl.40. The compound or salt of claim 26 , wherein Ris selected from the group consisting of tert-butyl claim 26 , perfluoroethyl claim 26 , and trifluoromethyl.41. The compound or salt of claim 26 , wherein Ris selected from the group consisting of furanyl claim 26 , pyrazolyl claim 26 , and thiophenyl claim 26 , wherein each such substituent optionally is substituted with methyl.42. The compound or salt of claim 26 , wherein Ris selected from the group consisting of C-C-alkenyl claim 26 , C-C-alkyl claim 26 , alkyloxy claim 26 , amino claim 26 , and halo.43. The compound or salt of claim 26 , wherein Ris methoxy.44. The compound or salt of claim 26 , wherein Ris selected from the group consisting of naphthalenyl claim 26 , dihydronaphthalenyl claim 26 , tetrahydronaphthalenyl claim 26 , hexahydronaphthalenyl claim 26 , octahydronaphthalenyl claim 26 , decahydronaphthalenyl claim 26 , ...

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 3. A method of treating HCV infection , comprising administering an effective amount of methyl {(2S ,3R)-1-[(2S)-2-{5-[(2R ,5R)-1-{3 ,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1H-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate or a pharmaceutically acceptable salt thereof , and an HCV protease inhibitor , to an HCV patient in need thereof.4. A method of treating HCV infection , comprising:making a pharmaceutical composition comprising methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1H-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate or a pharmaceutically acceptable salt thereof, and an HCV protease inhibitor; andadministering said pharmaceutical composition to an HCV patient in need thereof. The present application incorporates by reference the following patents and patent applications in their entireties: U.S. Patent Application Publication Nos. 2012/0004196, 2011/0207699, and 2011/0092415, and U.S. Pat. No. 8,691,938, and U.S. Provisional Application Ser. Nos. 61/186,291, 61/242,836, 61/243,596 and 61/446,800.The present invention relates to compounds effective in inhibiting replication of Hepatitis C virus (“HCV”). The present invention also relates to compositions comprising these compounds and methods of using these compounds to treat HCV infection.HCV is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family. The enveloped HCV virion ...

Antiviral compounds and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Antiviral Compounds And Uses Thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 3. The compound or salt of claim 1 , wherein Ris selected from the group consisting of hydrogen and methyl.4. The compound or salt of claim 1 , wherein Ris selected from the group consisting of hydrogen and methyl.5. The compound or salt of claim 1 , wherein Ris hydrogen.7. The compound or salt of claim 1 , wherein m is 0.8. The compound or salt of claim 1 , wherein m is 1.9. The compound or salt of claim 1 , wherein m is 2.10. The compound or salt of claim 1 , wherein m is 3.11. The compound or salt of claim claim 1 , wherein Ris hydrogen.12. The compound or salt of claim 1 , wherein Ris phenyl.13. The compound or salt of claim 1 , wherein Ris C-C-alkyl.14. The compound or salt of claim 1 , wherein Ris C-C-alkyloxy-carbonyl.15. The compound or salt of claim 1 , wherein Ris selected from the group consisting of C-C-alkyl claim 1 , C-C-carbocyclyl claim 1 , and 5-6-membered heterocyclyl claim 1 , wherein:{'sub': 1', '4, '(a) the C-C-alkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and'}{'sub': 3', '6, '(b) the C-C-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino.'}16. The compound or salt of claim 1 , wherein Ris selected from the group consisting of halo claim 1 , alkyl claim 1 , and alkyloxy.17. The compound or salt of claim 1 , wherein Ris selected from the group consisting of tert-butyl claim 1 , ...

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 2. The compound or salt of claim 1 , wherein:X is CH;{'sub': S', 'S', 'B', 'S', 'S, 'T is independently selected at each occurrence from —C(O)-L′-M′-L″- or —N(R)C(O)-L′-M′-L″-; and'}{'sub': S', '1', '6', 'T', 'S', 'S', 'S', 'S', 'S', 'S, 'L′ is independently C-Calkylene, and is independently optionally substituted at each occurrence with one or more substituents selected from halogen, R, —O—R, —S—R, —N(RR′), —OC(O)R, —C(O)OR, nitro, phosphonoxy, phosphono, oxo, thioxo, formyl or cyano.'}3. The compound or salt of claim 1 , wherein:{'sub': B', '1', '2', '5', 'D, 'Y is —N(R)C(O)C(RR)N(R)-T-R;'}{'sub': B', '8', '9', '12', 'D, 'Z is —N(R)C(O)C(RR)N(R)-T-R;'}{'sub': S', 'S, 'T is independently selected at each occurrence from —C(O)-L′-M′-L″-; and'}{'sub': 5', '6', 'M', 'M', 'S', 'E, 'D is C-Ccarbocycle, 5- to 6-membered heterocycle, or 6- to 10-membered bicycles, and is optionally substituted with one or more R, where Ris halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L-R.'}4. The compound or salt of claim 3 , wherein T is independently selected at each occurrence from —C(O)-L′-N(R)C(O)-L″- or —C(O)-L′-N(R)C(O)O-L″-.5. The compound or salt of claim 3 , wherein Ris halogen claim 3 , hydroxy claim 3 , mercapto claim 3 , amino claim 3 , carboxy claim 3 , nitro claim 3 , oxo claim 3 , phosphonoxy claim 3 , phosphono claim 3 , thioxo claim 3 , cyano; or C-Calkyl claim 3 , C-Calkenyl or C-Calkynyl claim 3 , each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen claim 3 , hydroxy claim 3 , mercapto claim 3 , amino claim 3 , carboxy claim 3 , nitro claim 3 , oxo claim 3 , phosphonoxy claim 3 , phosphono claim 3 , thioxo claim 3 , formyl or ...

ANTI-INFECTIVE AGENTS AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 1. (E)-N-(4-(3-tert-butyl-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide crystalline form selected from the group consisting of:crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide disodium salt nonahydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide disodium salt tetrahydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide dipotassium salt tetrahydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monopotassium salt trihydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monopotassium salt dihydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide 1/7 potassium salt;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monodiethylamine salt tetrahydrate;crystalline pattern A (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide;crystalline pattern B (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide;crystalline pattern C (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2- ...

ANTI-INFECTIVE AGENTS AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 1. A crystalline form of N-(6-(3-tert-butyl-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide and salts thereof.2. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of a solvate claim 1 , a hydrate and a solvent-free crystalline form.3. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of:crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide ethanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide acetonitrile solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide ethyl acetate solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide 2-propanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide methanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide 1-propanol solvate;crystalline solvent free N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl) ...

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula 2. The compound of wherein Ris OH and Ris H.3. The compound of wherein Ris OH claim 1 , Ris H claim 1 , X is O claim 1 , Y is O claim 1 , and Ris alkyl claim 1 , cycloalkenylalkyl claim 1 , cycloalkylalkyl claim 1 , heterocyclealkyl claim 1 , heteroarylalkyl claim 1 , arylalkyl claim 1 , hydroxyalkyl claim 1 , alkoxyalkyl claim 1 , -alkylSR claim 1 , -alkylSOR claim 1 , -alkylSORor -alkylNRR.4. The compound of wherein Ris OH claim 1 , Ris H claim 1 , X is O claim 1 , Y is O claim 1 , Ris alkyl or cycloalkylalkyl and Ris aryl or heteroaryl.5. The compound of wherein Ris OH claim 1 , Ris H claim 1 , Ris alkyl or cycloalkylalkyl claim 1 , X is O claim 1 , Y is O claim 1 , and Ris phenyl substituted with 0 claim 1 , 1 claim 1 , 2 claim 1 , 3 or 4 substituents selected from the group consisting of halo claim 1 , —OR claim 1 , —NRRand —C(R)═NOR; wherein Rand Rare independently selected from the group consisting of hydrogen and alkyl.6. The compound of or a pharmaceutically acceptable salt form claim 1 , stereoisomer claim 1 , ester claim 1 , salt of an ester claim 1 , prodrug claim 1 , salt of a prodrug claim 1 , or combination thereof claim 1 , selected from the group consisting ofhexahydrofuro[2,3-b]furan-3-yl (1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl]phenyl}sulfonyl)(isobutyl)amino]propylcarbamate;tetrahydro-3-furanyl (1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl]phenyl}sulfonyl)(isobutyl)amino]propylcarbamate;N-{(1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl]phenyl}sulfonyl)(isobutyl)amino]propyl}acetamide;N-{(1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl]phenyl}sulfonyl)(isobutyl)amino]propyl}-2-(2,6-dimethylphenoxy)acetamide;(3aS,7aR)-hexahydro-4H-furo[2,3-b]pyran-3-yl (1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl]phenyl}sulfonyl)(isobutyl)amino]propylcarbamate and (3aR,7aS)-hexahydro-4H-furo[2,3-b]pyran-3-yl (1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl] ...

HCV Protease Inhibitors and Uses Thereof

This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions. 3. The compound or salt of claim 1 , wherein each Ris independently selected from the group consisting of carbocyclyl claim 1 , heterocyclyl claim 1 , alkylcarbonyl claim 1 , alkenylcarbonyl claim 1 , alkynylcarbonyl claim 1 , alkyloxycarbonyl claim 1 , alkenyloxycarbonyl claim 1 , alkynyloxycarbonyl claim 1 , carbocyclylcarbonyl claim 1 , heterocyclylcarbonyl claim 1 , carbocyclyloxycarbonyl claim 1 , heterocyclyloxycarbonyl claim 1 , aminoalkylcarbonyl claim 1 , carbocyclylaminocarbonyl claim 1 , heterocyclylaminocarbonyl claim 1 , carbocyclylalkyloxycarbonyl claim 1 , heterocyclylalkyoxycarbonyl claim 1 , alkylcarbocyclylsulfonyl claim 1 , and alkylheterocyclylsulfonyl claim 1 , wherein:the amino portion of the aminoalkylcarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyloxycarbonyl, carbocyclylalkyloxycarbonyl, and heterocyclylalkyloxycarbonyl.4. The compound or salt of claim 1 , wherein each Ris independently selected from the group consisting of carbocyclyl claim 1 , heterocyclyl claim 1 , alkylcarbonyl claim 1 , alkyloxycarbonyl claim 1 , carbocyclylcarbonyl claim 1 , carbocyclyloxycarbonyl claim 1 , aminoalkylcarbonyl claim 1 , heterocyclylaminocarbonyl claim 1 , carbocyclylalkyloxycarbonyl claim 1 , and alkylcarbocyclylsulfonyl claim 1 , wherein:the amino portion of the aminoalkylcarbonyl optionally is substituted with one or two independently selected carbocyclylalkyloxycarbonyl.5. The compound or salt of claim 1 , wherein:{'sup': 8', 'B, 'Ris aminocarbonyl substituted with R; and'}{'sup': 'B', 'claim-text': the amino portion of the ...

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 14-. (canceled)5. A process of making methyl {(2S ,3R)-1-[(2S)-2-{5-[(2R ,5R)-1-{3 ,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1H-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate , or a pharmaceutically acceptable salt thereof , the process comprising:reacting (S)-6,6′-((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(5-fluoro-2((S)-pyrrolidin-2-yl)-1H-benzo[d]imidazole) with (2 S, 3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid.6. The process of claim 5 , wherein the reacting step is performed in the presence of a peptide coupling reagent.7. The process of claim 6 , wherein the peptide coupling reagent is selected from the group consisting of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride/1-hydroxybenzotriazole (EDAC/HOBT) claim 6 , (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) claim 6 , O-(7-azabenzotriazol-1-yl)-N claim 6 ,N claim 6 ,N′ claim 6 ,N′-tetramethyluronium hexafluorophosphate (HATU) claim 6 , propane phosphonic acid anhydride (T3P) claim 6 , and 3-(diethoxyphosphoryloxy)-1 claim 6 ,2 claim 6 ,3-benzotriazin-4(3H)-one (DEPBT).8. (S)-6 claim 6 ,6′-((2R claim 6 ,5R)-1-(3 claim 6 ,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2 claim 6 ,5-diyl)bis(5-fluoro-2((S)-pyrrolidin-2-yl)-1H-benzo[d]imidazole).9. A process of making methyl {(2S claim 6 ,3R)-1-[(2S)-2-{5-[(2R claim 6 ,5R)-1-{3 claim 6 ,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]pyrrolidin-2-yl}-1H- ...

Anti-Viral Compounds

The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 115-. (canceled)17. The compound of claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein Ris Br and Ris F or Ris Cl and Ris F.18. The compound of claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein Ris Br and Ris F.19. The compound of claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein Ris OH and Ris H.20. The compound of claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein Ris OH21. The compound of claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein X is O.22. The compound of claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein Ris selected from a group consisting of H claim 16 , D claim 16 , F claim 16 , N claim 16 , OCH claim 16 , CN claim 16 , OH claim 16 , 1H-tetrazol-5-yl claim 16 , 2H-tetrazol-2-yl claim 16 , 1H-tetrazol-1-yl claim 16 , 1H-imidazol-1-yl claim 16 , 1H-imidazol-2-yl and 1H-imidazol-5-yl.23. The compound of claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein said compound is selected from a group consisting of:(S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-4-bromo-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino) propanoate,(S)-isopropyl 2-(((S)-(((2R,3R,4S,5R)-4-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoateethyl 2-(((R)-(((2R,3R,4S,5R)-4-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate,ethyl 2-(((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3- ...

ANTI-VIRAL COMPOUNDS

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.Hepatitis C virus (“HCV”) is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome which encodes a single large polyprotein of about 3000 amino acids. The polyprotein comprises a core protein, envelope proteins E1 and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.HCV infection is associated with progressive liver pathology, including cirrhosis and hepatocellular carcinoma. Chronic hepatitis C may be treated with peginterferon-alpha in combination with ribavirin. Substantial limitations to efficacy and tolerability remain as many users suffer from side effects, and viral elimination from the body is often inadequate. Therefore, there is a need for new drugs to treat HCV infection.In one aspect, the present invention relates to a compound of Formula (XIII) or pharmaceutically acceptable salts thereof:whereinm and n are independently 0, 1, or 2;q and s are independently 0, 1, 2, 3, or 4;u and v are independently 0, 1, 2, or 3;A and B are selected from phenyl and a six-membered heteroaromatic ring containing one, two, or three nitrogen atoms; provided that at least one of A and B is other than phenyl; wherein at least one of A or B is substituted with -L-E or -L-D, wherein -L-E or -L-D is as defined below;X is selected from O, S, S(O), SO, CH, CHR, and C(R); provided that when n is 0, X is selected from CH, CHR, and C(R);Y is selected from O, S, S(O), SO, CH, CHR, and C(R); provided that when m is 0, Y is selected from CH, CHR, and C(R);each Rand Ris independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, ...

Antiviral Compounds and Uses Thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 2. (canceled)3. The compound or salt of claim 1 , wherein Ris selected from the group consisting of hydrogen and methyl.45-. (canceled)7. The compound or salt of claim 6 , wherein m is 0.8. The compound or salt of claim 1 , wherein m is 1.9. The compound or salt of claim 6 , wherein m is 2.10. The compound or salt of claim 6 , wherein m is 3.11. The compound or salt of claim 6 , wherein Ris hydrogen.12. The compound or salt of claim 6 , wherein Ris phenyl.13. The compound or salt of claim 6 , wherein Ris C-C-alkyl.14. The compound or salt of claim 6 , wherein Ris C-C-alkyloxy-carbonyl.15. The compound or salt of claim 1 , wherein Ris selected from the group consisting of C-C-alkyl claim 1 , C-C-carbocyclyl claim 1 , and 5-6-membered heterocyclyl claim 1 , wherein:{'sub': 1', '4, '(a) the C-C-alkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and'}{'sub': 3', '6, '(b) the C-C-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino.'}16. The compound or salt of claim 1 , wherein Ris selected from the group consisting of halo claim 1 , alkyl claim 1 , and alkyloxy.17. The compound or salt of claim 1 , wherein Ris selected from the group consisting of tert-butyl claim 1 , perfluoroethyl claim 1 , trifluoromethyl claim 1 , and 5-6-membered heterocyclyl optionally substituted with methyl.18. The compound or salt ...

ANTI-VIRAL COMPOUNDS

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. 14.-. (canceled)6. The compound of claim 5 , wherein D is phenyl.7. The compound of claim 5 , wherein A is heterocyclic.8. The compound of claim 5 , wherein Ris —R claim 5 , and Rat each occurrence is C-Calkyl optionally substituted with protected amino.9. The compound of claim 8 , wherein the protected amino is an amino group protected by a methoxycarbonyl.10. The compound of claim 5 , wherein A is heterocyclic; D is phenyl; Ris —R claim 5 , and Rat each occurrence is C-Calkyl optionally substituted with protected amino.11. The compound of claim 10 , wherein the protected amino is an amino group protected by a methoxycarbonyl.12. The compound of claim 5 , wherein A is a fused tricycle claim 5 , and one of the rings in said tricycle is further fused to an aromatic ring.13. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof.14. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof.15. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof.16. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof.17. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof.18. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof.19. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof.20. A method of treating HCV claim 5 , the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof. The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.Hepatitis ...

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 3. The method of claim 2 , wherein J is 3- to 6-membered heterocycle claim 2 , and is optionally substituted with one or more R.4. The method of claim 2 , wherein:{'sub': 'A', 'X is optionally substituted with one or more R;'}{'sub': 3', '6', 'A, 'J is C-Ccarbocycle or 3- to 6-membered heterocycle, and is optionally substituted with one or more R;'}{'sub': L', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S', '2', 'S', 'S', 'S', '5', 'S', '3', '6', '1', '6', '2', '6', '2', '6', '1', '6', '2', '6', '2', '6, 'Ris independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, —O—R, —S—R, —C(O)R, —OC(O)R, —C(O)OR, —N(RR′), —S(O)R, —SOR, —C(O)N(RR′) or —N(R)C(O)R′; or C-Ccarbocycle 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C-Calkyl, C-Calkenyl, C-Calkynyl, C-Chaloalkyl, C-Chaloalkenyl or C-Chaloalkynyl;'}{'sub': A', '1', '6', '2', '6', '2', '6', '3', '6', '1', '6', '2', '6', '2', '6', '1', '6', '2', '6', '2', '6, 'Ris independently selected at each occurrence from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C-Calkyl, C-Calkenyl or C-Calkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C-Ccarbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from ...

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 2. The compound or salt of claim 1 , wherein:{'sub': 1', '5', '6', '1', '7', '5', '6', 'A, 'Ais C-Ccarbocyclyl or 5- to 6-membered heterocyclyl, and is substituted with —X—R, wherein said C-Ccarbocyclyl and 5- to 6-membered heterocyclyl are optionally substituted with one or more R;'}{'sub': 2', '5', '6', '2', '8', '5', '6', 'A, 'Ais C-Ccarbocyclyl or 5- to 6-membered heterocyclyl, and is substituted with —X—R, wherein said C-Ccarbocyclyl and 5- to 6-membered heterocyclyl are optionally substituted with one or more R;'}{'sub': 3', '4', 'A', '3', '4', '5', '6', '5', '6', 'A, 'Rand Rare each independently selected from hydrogen or R; or Rand R, taken together with the carbon atoms to which they are attached, form a C-Ccarbocyclic or 5- to 6-membered heterocyclic ring, wherein said C-Ccarbocyclic and 5- to 6-membered heterocyclic ring are optionally substituted with one or more R; and'}{'sub': 5', '6', 'A', '5', '6', '5', '6', '5', '6', 'A, 'Rand Rare each independently selected from hydrogen or R; or Rand R, taken together with the carbon atoms to which they are attached, form a C-Ccarbocyclic or 5- to 6-membered heterocyclic ring, wherein said C-Ccarbocyclic and 5- to 6-membered heterocyclic ring are optionally substituted with one or more R.'}3. The compound or salt of claim 2 , wherein at least one of Rand Ris C-Ccarbocyclyl or 5- to 6-membered heterocyclyl claim 2 , and is optionally substituted with one or more R.4. The compound or salt of claim 2 , wherein said at least one of Rand Ris phenyl claim 2 , and is optionally substituted with one or more R.5. The compound or salt of claim 2 , wherein Rand Rare independently selected from C-Ccarbocyclyl or 5- to 6-membered heterocyclyl claim 2 , and at each ...

ANTI-VIRAL COMPOUNDS

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. 1. A compound of Formula (I) or pharmaceutically acceptable salts thereof:{'sub': 2', 'n', '2', 'p', '2', 'n', '2', 'p', '2', 'n', '2', 'p', '2', 'n', 'k', '2', 'p', '2', 'n', '2', 'p', '2', 'n', 'N', '2', 'p', '2', 'n', '2', 'p', '2', 'n', 'k', '2', 'p', '2', 'n', '2', 'p, 'sup': N', 'N', 'N', 'N', 'N', 'N', 'N, 'A and A′ are independently selected from the group consisting of a single bond, —(CR)—C(O)—(CR)—, —(CR)—O—(CR)—, —(CR)—N(R)—(CR)—, —(CR)—S(O)—N(R)—(CR)—, —(CR)—C(O)—N(R)—(CR)—, —(CR)—N(R)—C(O)—N(R)—(CR)—, —(CR)—C(O)—O—(CR)—, —(CR)—N(R)—S(O)—N(R)—(CR)— and —(CR)—N(R)—C(O)—O—(CR)— and a heteroaryl group selected from the group consisting of'}{'sup': '1', 'sub': '2', 'Xis CH, NH, O or S,'}{'sup': 1', '2', '1, 'Y, Yand Zare each independently CH or N,'}{'sup': '2', 'Xis NH, O or S,'}{'sub': 2', '2', '2', 'a', '2', 'b, 'sup': 'N', 'V is —CH—CH—, —CH═CH—, —N═CH—, (CH)—N(R)—(CH)— or'}{'sub': 2', 'a', '2', 'b, '—(CH)—O—(CH)—, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,'}wherein:{'sub': 2', '1', '12', '1', '12, 'the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of —OH, —CN, —NO, halogen, C-Calkyl, C-Cheteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,'}{'sub': 1', '12', '1', '12, 'the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of —OH, Cto Calkyl, Cto Cheteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,'}a and b are independently 1, 2, or 3.c and d are independently 1 or 2,n ...

Anti-Infective Agents and Uses Thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 1. A crystalline form of N-(6-(3-tert-butyl-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide and salts thereof.2. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of a solvate claim 1 , a hydrate and a solvent-free crystalline form.3. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of:crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide ethanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide acetonitrile solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide ethyl acetate solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide 2-propanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide methanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide 1-propanol solvate;crystalline solvent free N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl) ...

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 6. The compound or salt of claim 5 , wherein:{'sub': S', 'S', 'B', 'S', 'S, 'T is independently selected at each occurrence from —C(O)-L′-M′-L″- or —N(R)C(O)-L′-M′-L″-; and'}{'sub': S', '1', '6', 'L, 'L′ is each independently C-Calkylene, and is independently optionally substituted at each occurrence with one or more R.'}7. The compound or salt of claim 5 , wherein:{'sub': B', '1', '2', '5', 'D, 'Y is —N(R)C(O)C(RR)N(R)-T-R;'}{'sub': B', '8', '9', '12', 'D, 'Z is —N(R)C(O)C(RR)N(R)-T-R;'}{'sub': S', 'S, 'T is independently selected at each occurrence from —C(O)-L′-M′-L″-; and'}{'sub': 5', '6', 'A, 'D is C-Ccarbocycle, 5- to 6-membered heterocycle, or 6- to 10-membered bicycles, and is substituted with one or more R.'}11. A process of making an HCV inhibitor according to a scheme selected from Scheme I to Scheme XXV. This application is a continuation of U.S. patent application Ser. No. 14/180,886, filed Feb. 14, 2014, which is a divisional of Ser. No. 12/813,301, filed Jun. 10, 2010 and now U.S. Pat. No. 8,691,938, which claims the benefit from U.S. Provisional Application Ser. No. 61/186,291 filed Jun. 11, 2009, U.S. Provisional Application Ser. No. 61/242,836 filed Sep. 16, 2009, and U.S. Provisional Application Ser. No. 61/243,596 filed Sep. 18, 2009; all of these applications are incorporated herein by reference in their entireties.The present invention relates to compounds effective in inhibiting replication of Hepatitis C virus (“HCV”). The present invention also relates to compositions comprising these compounds and methods of using these compounds to treat HCV infection.HCV is an RNA virus belonging to the genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome ...

ANTI-VIRAL COMPOUNDS

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. 1. A compound of Formula (I) or pharmaceutically acceptable salts thereof:{'sub': 2', 'n', '2', 'p', '2', 'n', '2', 'p', '2', 'n', '2', 'p', '2', 'n', 'k', '2', 'p', '2', 'n', 'k', '2', 'p', '2', 'n', '2', 'p', 'n', '2', 'p', '2', 'n', '2', 'p', '2', 'n', 'k', '2', 'p', '2', 'n', '2', 'p, 'sup': N', 'N', 'N', '2', 'N', 'N', 'N', 'N', 'N, 'A and A′ are independently selected from the group consisting of a single bond, —(CR)—C(O)—(CR)—, —(CR)—O—(CR)—, —(CR)—N(R)—(CR), —(CR)—S(O)—(CR)—, —(CR)—S(O)—N(R)—(CR)—, —(CR)—C(O)—N(R)—(CR)—, —(CR)—N(R)—C(O)—N(R)—(CR), —(CR)—C(O)—O—(CR)—, —(CR)—N(R)—S(O)—N(R)—(CR)— and —(CR)—N(R)—C(O)—O—(CR)— and a heteroaryl group selected from the group'}consisting ofwherein:{'sup': '1', 'sub': '2', 'Xis CH, NH, O or S,'}{'sup': 1', '2', '1, 'Y, Yand Zare each independently CH or N,'}{'sup': '2', 'Xis NH, O or S,'}{'sub': 2', '2', '2', 'a', '2', 'b', '2', 'a', '2', 'b, 'sup': 'N', 'V is —CH—CH—, —CH═CH—, —N═CH—, (CH)—N(R)—(CH)— or —(CH)—O—(CH)—, wherein a and b are independently 0, 1, 2 or 3 with the proviso that a and b are not both 0,'}{'sub': 1', '12', '1', '12, 'the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of —OH, Cto Calkyl, Cto Cheteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,'}a and b are independently 1, 2 or 3.c and d are independently 1 or 2,n and p are independently 0, 1, 2 or 3,k is 0, 1 or 2,{'sub': 2', '1', '12', '1', '12, 'each R is independently selected from the group consisting of hydrogen, —OH, —CN, —NO, halogen, Cto Calkyl, Cto Cheteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, ...

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 6. The method of claim 5 , wherein:{'sub': S', 'S', 'B', 'S', 'S, 'T is independently selected at each occurrence from —C(O)-L′-M′-L″- or —N(R)C(O)-L′-M′-L″-; and'}{'sub': S', '1', '6', 'L, 'L′ is each independently C-Calkylene, and is independently optionally substituted at each occurrence with one or more R.'}7. The method of claim 5 , wherein:{'sub': B', '1', '2', '5', 'D, 'Y is —N(R)C(O)C(RR)N(R)-T-R;'}{'sub': B', '8', '9', '12', 'D, 'Z is —N(R)C(O)C(RR)N(R)-T-R;'}{'sub': S', 'S, 'T is independently selected at each occurrence from —C(O)-L′-M′-L″-; and'}{'sub': 5', '6', 'A, 'D is C-Ccarbocycle, 5- to 6-membered heterocycle, or 6- to 10-membered bicycles, and is substituted with one or more R.'} This application is a divisional of U.S. patent application Ser. No. 12/813,301 filed Jun. 10, 2010, which claims the benefit from U.S. Provisional Application Ser. No. 61/186,291 filed Jun. 11, 2009, U.S. Provisional Application Ser. No. 61/242,836 filed Sep. 16, 2009, and U.S. Provisional Application Ser. No. 61/243,596 filed Sep. 18, 2009; all of these applications are incorporated herein by reference in their entireties.The present invention relates to compounds effective in inhibiting replication of Hepatitis C virus (“HCV”). The present invention also relates to compositions comprising these compounds and methods of using these compounds to treat HCV infection.HCV is an RNA virus belonging to the genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome encoding all known virus-specific proteins in a single, uninterrupted, open reading frame. The open reading frame comprises approximately 9500 nucleotides and encodes a single large polyprotein of about 3000 amino acids. The ...

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

ANTI-VIRAL COMPOUNDS

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.Hepatitis C virus (“HCV”) is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome which encodes a single large polyprotein of about 3000 amino acids. The polyprotein comprises a core protein, envelope proteins E1 and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.HCV infection is associated with progressive liver pathology, including cirrhosis and hepatocellular carcinoma. Chronic hepatitis C may be treated with peginterferon-alpha in combination with ribavirin. Substantial limitations to efficacy and tolerability remain as many users suffer from side effects, and viral elimination from the body is often inadequate. Therefore, there is a need for new drugs to treat HCV infection.In one aspect, the present invention relates to a compound of Formula (VIII) or pharmaceutically acceptable salts thereof:wherein:A is independently selected from the group consisting of: aryl, heteroaryl, heterocyclic, C-Ccycloalkyl, and C-Ccycloalkenyl, all optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, —R, OR, N(R), —C(O)R, —COR, C(O)N(R)and —N(R)C(O)R, wherein A is substituted with -L-E or preferably -L-D, wherein -L-E or -L-D are as defined below;Rat each occurrence is independently C-Calkyl optionally substituted with one or more halogen atoms;Rat each occurrence is independently hydrogen or optionally substituted C-Calkyl;Rand Rat each occurrence are each independently selected from the group consisting of: hydrogen, halogen, cyano, optionally substituted C-Calkyl, —O—R, —NRR, —C(O)R, —COR, and —C(O ...

ANTI-VIRAL COMPOUNDS

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.Hepatitis C virus (“HCV”) is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome which encodes a single large polyprotein of about 3000 amino acids. The polyprotein comprises a core protein, envelope proteins E1 and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.HCV infection is associated with progressive liver pathology, including cirrhosis and hepatocellular carcinoma. Chronic hepatitis C may be treated with peginterferon-alpha in combination with ribavirin. Substantial limitations to efficacy and tolerability remain as many users suffer from side effects, and viral elimination from the body is often inadequate. Therefore, there is a need for new drugs to treat HCV infection.In another aspect, the present invention relates to a compound of Formula (II) or pharmaceutically acceptable salts thereof:wherein:A is (a) absent; or (b) a cyclic group independently selected from aryl, heteroaryl, heterocyclic, C-Ccycloalkyl, and C-Ccycloalkenyl, each optionally substituted; wherein A, when or if present, is preferably substituted with -L-E or -L-D, wherein L, E, Land D are defined as below;Y is (a) absent; or (b) an optionally substituted aliphatic group selected from the group consisting of O, S, N(R), C-C, alkyl, C-C, alkenyl, C-C, alkynyl, C-C, cycloalkyl, C-Ccycloalkenyl, and heterocyclic, each optionally substituted; or a combination thereof; wherein Y, if or when present, is optionally substituted with -L-E or -L-D, wherein L, E, Land D are defined as below;Z is (a) absent; or (b) an optionally substituted linear aliphatic group; optionally Z contains ...

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Anti-viral compounds to treat hcv infection

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

ANTI-VIRAL COMPOUNDS Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds and methods of identifying the same

Methods of identifying NS5A inhibitors are provided. Novel binding sites are identified on NS5A dimers, and these binding sites can be used to design and/or identify new NS5A inhibitors.

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Antiviral compounds

Un compuesto, un tautómero del compuesto, o una sal aceptable desde el punto de vista farmacéutico delcompuesto o tautómero, en donde el compuesto se selecciona del grupo que consiste en:un compuesto que tiene la Fórmula II:en donde:R6 se selecciona del grupo que consiste en hidrógeno y ciano;R8 se selecciona del grupo que consiste en hidrógeno y arilalquilo;R25 se selecciona del grupo que consiste en hidrógeno y alquilo;R37 se selecciona del grupo que consiste en hidrógeno, alquilo, hidroxialquilo, y cicloalquilo;R42 se selecciona del grupo que consiste en arilsulfanilo, heteroarilsulfanilo, y ariloxi; en donde R42 estásustituido en forma opcional con uno o más sustituyentes seleccionados en forma independiente de R46;R46 es uno o más sustituyentes seleccionados del grupo que consiste en hidrógeno, hidroxi, amino,halógeno, dialquilamino, y alcoxicarbonilamino;R70 se selecciona del grupo que consiste en arilo, y heterociclo; en donde R70 está sustituido en formaopcional con R75;R75 es uno o más sustituyentes seleccionados en forma independiente del grupo que consiste enhidrógeno, halógeno, alcoxi, ciano, alquilo, haloalquilo, y arilo.un compuesto que tiene la Fórmula III: A compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound is selected from the group consisting of: a compound having Formula II: wherein: R6 is selected from the group consisting of hydrogen and cyano; R8 is selected from the group consisting of hydrogen and arylalkyl; R25 is selected from the group consisting of hydrogen and alkyl; R37 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and cycloalkyl; R42 is selects from the group consisting of arylsulfanyl, heteroarylsulfanyl, and aryloxy; wherein R42 is optionally substituted with one or more substituents independently selected from R46; R46 is one or more substituents selected from the group consisting of hydrogen, hydroxy, amino, halogen, dialkylamino, ...

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Antiviral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative

Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Anti-viral compounds

This invention relates to processes and intermediates for making compounds which are effective in inhibiting replication of Hepatitis C virus (HCV).

Anti-viral compounds

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Anti-viral compounds

Anti-viral compounds

Anti-viral compounds

Hepatitis C virus inhibitors

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Anti-viral compounds

The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Hepatitis C virus inhibitors

Anti-viral compounds.

Se describen compuestos efectivos para inhibir la replicación del virus de la Hepatitis C (VHC). Esta invención también se refiere a procedimientos para elaborar dichos compuestos, a composiciones que comprenden dichos compuestos, y a métodos para utilizar dichos compuestos para tratar infección por VHC.

Anti-viral compounds.

Se describen compuestos efectivos para inhibir la replicación del virus de Hepatitis C ("VHC"). La presente invención también se refiere a los procesos de fabricación de estos compuestos, composiciones que comprenden estos compuestos y método de uso de estos compuestos para tratar la infección con VHC.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Anti-viral compounds

Anti-viral compounds

Anti-viral compounds

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds.

Se describen compuestos efectivos para inhibir la replicación del virus de la Hepatitis C ("VHC"). Esta invención también se refiere a procedimientos para elaborar dichos compuestos, a composiciones que comprenden dichos compuestos, y a métodos para utilizar dichos compuestos para tratar infección por VHC.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Antiviral compounds

El compuesto {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}-5-(6-fluoro-2- {(2S)-1-[N-(metoxicarbonil)-O-metil-L-treonil]pirrolidin-2-il}-1H-benzimidazol-5-il)pirrolidin-2-il]-6-fluoro-1H-benzimidazol-2il}pirrolidin-1-il]-3-metoxi-1-oxobutan-2-il}carbamato de metilo, o una de sus sales farmacéuticamente aceptables, para su uso en un método de tratamiento de un paciente infectado con el genotipo 1 del VHC, comprendiendo dicho método la administración de una cantidad eficaz de dicho compuesto a dicho paciente. The compound {(2S, 3R) -1 - [(2S) -2- {5 - [(2R, 5R) -1- {3,5-difluoro-4- [4- (4-fluorophenyl) piperidin-1 -yl] phenyl} -5- (6-fluoro-2- {(2S) -1- [N- (methoxycarbonyl) -O-methyl-L-threonyl] pyrrolidin-2-yl} -1H-benzimidazol-5- il) methyl pyrrolidin-2-yl] -6-fluoro-1H-benzimidazol-2-yl} pyrrolidin-1-yl] -3-methoxy-1-oxobutan-2-yl} carbamate, or a pharmaceutically acceptable salt thereof, for use in a method of treating a patient infected with HCV genotype 1, said method comprising administering an effective amount of said compound to said patient.

Heterocyclic compounds as hepatitis C virus (HCV) inhibitors

Un compuesto de Fórmula IB, o una de sus sales farmacéuticamente aceptables,**Fórmula** donde: X es heterociclo de 3 a 12 miembros, y está opcionalmente sustituido con uno o más RA; cada uno de L1 y L2 se selecciona independientemente entre enlace; o alquileno C1-C6, alquileno C2-C6 o alquinileno C2-C6, cada uno de los cuales está, independientemente, sustituido en cada caso opcionalmente con uno o más RL; L3 es enlace o -LS-K-LS'-, donde K se selecciona entre enlace, -O-, -S-, -N(RB)-, -C(O)-, -S(O)2-, -S(O)-, -OS(O)-, -OS(O)2-, -S(O)O-, -S(O)O-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)N(RB)-, -N(RB)C(O)-, -N(RB)C(O)O-, -OC(O)N(RB)-, -N(RB)S(O)-, -N(RB)S(O)2-, -S(O)N(RB)-, -S(O)2N(RB)-, -C(O)N(RB)C(O)-, -N(RB)C(O)N(RB'), -N(RB)SO2N(RB')-, o -N(RB)S(O)N(RB')-; A es**Fórmula** o**Fórmula** y está opcionalmente sustituido con uno o más RA;**Fórmula** B es**Fórmula** o**Fórmula** y está opcionalmente sustituido con uno o más RA; Z1 se selecciona independientemente en cada caso entre O, S, NH o CH2; Z2 se selecciona independientemente en cada caso entre N o CH; D es carbociclo C3-C1 o heterociclo de 3 a 12 miembros, que está sustituido con J y opcionalmente sustituido con uno o más RA, donde J es carbociclo C3-C1 o heterociclo de 3 a 12 miembros y está opcionalmente sustituido con uno o más RA, o J es -SF5; cada RC' se selecciona independientemente entre RC; cada RD se selecciona independientemente entre RD; R2 y R5, tomados junto con los átomos a los que están unidos, forman un heterociclo de 3 a 12 miembros que está opcionalmente sustituido con uno o más RA; y R9 y R12, tomados junto con los átomos a los que están unidos, forman un heterociclo de 3 a 12 miembros que está opcionalmente sustituido con uno o más RA; T se selecciona independientemente en cada caso entre enlace, -LS-, -LS-M-LS'-, o -LS-M-LS'-M'-LS"-, donde cada M y M' se selecciona independientemente en cada caso entre enlace, -O-, -S-, -N(RB)-, -C(O)-, -S(O)2-, -S(O)-, -OS ...

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds.

Se describen compuestos efectivos para inhibir la replicación del virus de la Hepatitis C ("VHC"). Esta invención también se refiere a procedimientos para elaborar dichos compuestos, a composiciones que comprenden dichos compuestos, y a métodos para utilizar dichos compuestos para tratar infección por VHC.

Anti-viral compounds

本發明描述一種可有效抑制C型肝炎病毒(「HCV」)複製之化合物。本發明亦關於製備該等化合物之方法，包含該等化合物之組合物，及使用該等化合物來治療HCV感染之方法。

antiviral compound and pharmaceutical composition comprising said compound

compostos antivirais. compostos eficazes em inibir a replicação do vírus da hepatite c ("hcv") são descritos. esta invenção também refere-se a processos para preparar tais compostos, a composições compreendendo tais compostos e a métodos de uso de tais compostos para tratar infecção por hcv. antiviral compounds. compounds effective in inhibiting hepatitis c virus ("hcv") replication are described. this invention also relates to processes for preparing such compounds, compositions comprising such compounds and methods of using such compounds to treat hcv infection.

Anti-viral compounds to treat hcv infection.

Se describen compuestos efectivos para inhibir la replicación del Virus de Hepatitis C ("VHC"). Esta invención también se refiere a procedimientos para elaborar dichos compuestos, a composiciones que comprenden dichos compuestos, y a métodos para utilizar dichos compuestos para tratar infección por VHC.

Anti-viral compounds to treat hcv infection

Anti-viral compounds to treat hcv infection

Anti-viral compounds to treat hcv infection

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Antiviral compounds to treat HCV infection

Un compuesto o una de sus sales farmacéuticamente aceptables, donde dicho compuesto tiene la Fórmula IB **Fórmula** donde: X es carbociclo C3-C12, y está opcionalmente sustituido con uno o más Ra; cada RC se selecciona independientemente entre Rc; cada RD se selecciona independientemente entre Rd; R2 y R5, tomados junto con los átomos a los que están unidos, forma un heterociclo de 3 a 12 miembros que está opcionalmente sustituido con uno o más Ra; y R9 y R12, tomados junto con los átomos a los que están unidos, forma un heterociclo de 3 a 12 miembros que está opcionalmente sustituido con uno o más Ra; cada Rd se selecciona independientemente en cada caso entre hidrógeno o Ra; R6 se selecciona independientemente en cada caso entre halógeno, nitro, oxo, fosfonoxi, fosfono, tioxo, ciano, o -Ls-Re, donde dos Ra adyacentes, tomados junto con los átomos a los que están unidos, y cualesquiera átomos situados entre los átomos a los que están unidos, puede formar opcionalmente un carbociclo o heterociclo; Rb se selecciona independientemente en cada caso entre hidrógeno, o alquilo C1-C9, alquenilo C2-C6 o alquinilo C2-C6, cada uno de los cuales está, de manera independiente, sustituido en cada caso de manera opcional con uno o más sustituyentes seleccionados entre halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano o carbociclo o heterociclo de 3 a 6 miembros; o carbociclo o heterociclo de 3 a 6 miembros; donde cada carbociclo o heterociclo de 3 a 6 miembros en Rc está, de manera independiente, sustituido en cada caso de manera opcional con uno o más sustituyentes seleccionados entre halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano, alquilo C1-C9, alquenilo C2-6, alquenilo C2-C6, haloalquilo C1-C9, haloalquenilo C2-C6 o haloalquinilo C2-C6; Rc se selecciona independientemente en cada caso entre hidrógeno, halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono ...

Anti-viral compounds

Compounds for Formula I effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. (see formula I)